328 related articles for article (PubMed ID: 30477009)
1. Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial.
Kazandjian D; Korde N; Mailankody S; Hill E; Figg WD; Roschewski M; Landgren O
JAMA Oncol; 2018 Dec; 4(12):1781-1783. PubMed ID: 30477009
[TBL] [Abstract][Full Text] [Related]
2. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial.
Dimopoulos MA; Lonial S; Betts KA; Chen C; Zichlin ML; Brun A; Signorovitch JE; Makenbaeva D; Mekan S; Sy O; Weisel K; Richardson PG
Cancer; 2018 Oct; 124(20):4032-4043. PubMed ID: 30204239
[TBL] [Abstract][Full Text] [Related]
3. Final results of a phase I study of carfilzomib, lenalidomide, and dexamethasone for heavily pretreated multiple myeloma.
Sugiura I; Suzuki K; Ri M; Chou T; Takezako N; Sunami K; Ishida T; Izumi T; Ozaki S; Shumiya Y; Iida S
Int J Hematol; 2020 Jan; 111(1):57-64. PubMed ID: 31664647
[TBL] [Abstract][Full Text] [Related]
4. Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m
Korde N; Mastey D; Tavitian E; Mailankody S; Lesokhin A; Hassoun H; Smith EL; Lendvai N; Hultcrantz M; Shah U; Tan C; Lu S; Diamond B; Salcedo M; Werner K; Chung DJ; Scordo M; Shah GL; Lahoud O; Landau H; Arcila M; Ho C; Roshal M; Dogan A; Derkach A; Devlin SM; Giralt SA; Landgren O
Am J Hematol; 2021 Jun; 96(6):E193-E196. PubMed ID: 33661527
[No Abstract] [Full Text] [Related]
5. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
[TBL] [Abstract][Full Text] [Related]
6. The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy.
Tzogani K; Camarero Jiménez J; Garcia I; Sancho-López A; Martin M; Moreau A; Demolis P; Salmonson T; Bergh J; Laane E; Ludwig H; Gisselbrecht C; Pignatti F
Oncologist; 2017 Nov; 22(11):1339-1346. PubMed ID: 28935772
[TBL] [Abstract][Full Text] [Related]
7. A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Lee HC; Shah JJ; Feng L; Manasanch EE; Lu R; Morphey A; Crumpton B; Patel KK; Wang ML; Alexanian R; Thomas SK; Weber DM; Orlowski RZ
Blood Cancer J; 2019 Oct; 9(10):80. PubMed ID: 31575851
[No Abstract] [Full Text] [Related]
8. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.
Usmani SZ; Schjesvold F; Oriol A; Karlin L; Cavo M; Rifkin RM; Yimer HA; LeBlanc R; Takezako N; McCroskey RD; Lim ABM; Suzuki K; Kosugi H; Grigoriadis G; Avivi I; Facon T; Jagannath S; Lonial S; Ghori RU; Farooqui MZH; Marinello P; San-Miguel J;
Lancet Haematol; 2019 Sep; 6(9):e448-e458. PubMed ID: 31327689
[TBL] [Abstract][Full Text] [Related]
9. A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Lee HC; Shah JJ; Feng L; Morphey A; Johnson RJ; Wesson ET; Wang ML; Alexanian R; Thomas SK; Orlowski RZ; Weber DM
Am J Hematol; 2019 Dec; 94(12):E319-E322. PubMed ID: 31489991
[No Abstract] [Full Text] [Related]
10. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
Wang M; Martin T; Bensinger W; Alsina M; Siegel DS; Kavalerchik E; Huang M; Orlowski RZ; Niesvizky R
Blood; 2013 Oct; 122(18):3122-8. PubMed ID: 24014245
[TBL] [Abstract][Full Text] [Related]
11. Carfilzomib weekly 20/56 mg/m
Richez V; Gruchet C; Guidez S; Fouquet G; Azais I; Durand G; Javaugue V; Brigaud A; Plasse F; Diolez J; Machet A; Moya N; Gardeney H; Franques P; Bobin A; Levy A; Sabirou F; Bonnin A; Dieval C; Primault S; Barrier J; Fleck E; Bouyier S; Daras C; Princet I; Bauwens D; Legros L; Fuzibet JG; Gil A; Bridoux F; Avet-Loiseau H; Leleu X
Am J Hematol; 2019 Jan; 94(1):E17-E20. PubMed ID: 30358902
[No Abstract] [Full Text] [Related]
12. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Stewart AK; Rajkumar SV; Dimopoulos MA; Masszi T; Špička I; Oriol A; Hájek R; Rosiñol L; Siegel DS; Mihaylov GG; Goranova-Marinova V; Rajnics P; Suvorov A; Niesvizky R; Jakubowiak AJ; San-Miguel JF; Ludwig H; Wang M; Maisnar V; Minarik J; Bensinger WI; Mateos MV; Ben-Yehuda D; Kukreti V; Zojwalla N; Tonda ME; Yang X; Xing B; Moreau P; Palumbo A;
N Engl J Med; 2015 Jan; 372(2):142-52. PubMed ID: 25482145
[TBL] [Abstract][Full Text] [Related]
13. Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial.
Lee JH; Park Y; Kang KW; Lee JJ; Lee HS; Eom HS; Do YR; Kim JS; Yoon SS; Shin DY; Koh Y; Kim KH; Lee WS; Jo JC; Lee YJ; Lee JY; Kim DS; Shim H; Chang MH; Kim SH; Min CK;
Ann Hematol; 2021 Aug; 100(8):2051-2059. PubMed ID: 33447888
[TBL] [Abstract][Full Text] [Related]
14. A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.
Alsina M; Landgren O; Raje N; Niesvizky R; Bensinger WI; Berdeja JG; Kovacsovics T; Vesole DH; Fang B; Kimball AS; Siegel DS
Am J Hematol; 2021 Feb; 96(2):226-233. PubMed ID: 33125764
[TBL] [Abstract][Full Text] [Related]
15. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
[TBL] [Abstract][Full Text] [Related]
16. Daratumumab plus lenalidomide and dexamethasone
Dimopoulos MA; San-Miguel J; Belch A; White D; Benboubker L; Cook G; Leiba M; Morton J; Ho PJ; Kim K; Takezako N; Moreau P; Kaufman JL; Sutherland HJ; Lalancette M; Magen H; Iida S; Kim JS; Prince HM; Cochrane T; Oriol A; Bahlis NJ; Chari A; O'Rourke L; Wu K; Schecter JM; Casneuf T; Chiu C; Soong D; Sasser AK; Khokhar NZ; Avet-Loiseau H; Usmani SZ
Haematologica; 2018 Dec; 103(12):2088-2096. PubMed ID: 30237262
[TBL] [Abstract][Full Text] [Related]
17. Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.
Hájek R; Minařík J; Straub J; Pour L; Jungova A; Berdeja JG; Boccadoro M; Brozova L; Spencer A; van Rhee F; Vela-Ojeda J; Thompson MA; Abonour R; Chari A; Cook G; Costello CL; Davies FE; Hungria VT; Lee HC; Leleu X; Puig N; Rifkin RM; Terpos E; Usmani SZ; Weisel KC; Zonder JA; Bařinová M; Kuhn M; Šilar J; Čápková L; Galvez K; Lu J; Elliott J; Stull DM; Ren K; Maisnar V
Future Oncol; 2021 Jul; 17(19):2499-2512. PubMed ID: 33769076
[TBL] [Abstract][Full Text] [Related]
18. Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma.
Ailawadhi S; Sexton R; Lentzsch S; Abidi MH; Voorhees PM; Cohen AD; Rohren EM; Heitner S; Kelly K; Mackler NJ; Baer DM; Hoering A; Durie B; Orlowski RZ
Clin Cancer Res; 2020 Aug; 26(15):3969-3978. PubMed ID: 32299820
[TBL] [Abstract][Full Text] [Related]
19. Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis.
Arcuri LJ; Americo AD
Ann Hematol; 2021 Mar; 100(3):725-734. PubMed ID: 33432438
[TBL] [Abstract][Full Text] [Related]
20. Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.
Dimopoulos MA; Stewart AK; Masszi T; Špička I; Oriol A; Hájek R; Rosiñol L; Siegel D; Mihaylov GG; Goranova-Marinova V; Rajnics P; Suvorov A; Niesvizky R; Jakubowiak A; San-Miguel J; Ludwig H; Ro S; Aggarwal S; Moreau P; Palumbo A
Blood Cancer J; 2017 Apr; 7(4):e554. PubMed ID: 28430175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
